Paul Workman, PhD was Chief Executive and President of The Institute of Cancer Research (ICR), London from 2014 to 2021. He is Harrap Professor of Pharmacology and Therapeutics at the ICR, as well as the former Head of the Division of Cancer Therapeutics and former Director of the Cancer Research UK Cancer Therapeutics Unit from 1997-2016. Paul is also a Fellow of the Academy of Medical Sciences, the Royal Society of Medicine, the Royal Society of Chemistry and the Royal Society of Biology and is a Cancer Research UK Life Fellow.
Paul is a leader in the field of molecularly targeted cancer drugs and his research focus is the discovery and development of cancer drugs that exploit our knowledge of the cancer genome and cancer biology toward the goal of personalised medicine. Under his leadership, the Cancer Research UK Cancer Therapeutics Unit at ICR identified 20 clinical drug candidates, progressed 11 of its drugs into Phase I clinical trials in ICR’s partner Royal Marsden Hospital, and has seen its prostate cancer drug approved by the US FDA, European Medicines Agency and NICE and successfully launched.
Paul was awarded a PhD in cancer pharmacology from the University of Leeds. His previous research experience encompasses positions in Cambridge University, Stanford University, Glasgow University as well as a pharmaceutical position with AstraZeneca.
Paul has also been the scientific founder of two successful biotech companies: Piramed Pharma, which was acquired by Roche in 2008 and Chroma Therapeutics.